Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press21510.17650/1726-9776-2009-5-2-7-14LECTUREЛЕКЦИЯPROGNOSTIC FACTORS IN PATIENTS WITH RENAL-CELL CARCINOMA AND A ROLE OF ONCOPHAGE IN INCREASING SURVIVAL RATES AFTER SURGICAL TREATMENTПРОГНОСТИЧЕСКИЕ ФАКТОРЫ У БОЛЬНЫХ ПОЧЕЧНО-КЛЕТОЧНЫМ РАКОМ И РОЛЬ ОНКОФАГА В УЛУЧШЕНИИ ВЫЖИВАЕМОСТИ ПОСЛЕ ХИРУРГИЧЕСКОГО ЛЕЧЕНИЯAlekseyevB. Ya.АлексеевБ. Я.
Russian Federation
byalekseev@mail.ruFrankG. A.ФранкГ. А.
Russian Federation
byalekseev@mail.ruAndreyevaYu. Yu.АндрееваЮ. Ю.
Russian Federation
byalekseev@mail.ruKalpinskyA. S.КалпинскийА. С.
Russian Federation
byalekseev@mail.ruP.A. Herzen Moscow Research Oncological InstituteМНИОИ им. П.А. Герцена30062009527140108201401082014https://oncourology.abvpress.ru/oncur/article/view/215

The prognostic value of the Fuhrman renal-cell carcinoma (RCC) gradation system has been supported by numerous studies. The high RCC  grade after Fuhrman is a sign of the high risk of recurrence even in patients with the early stages of the disease, in clear-cell tumor in par-  ticular. The anticancer vaccine Oncophage is recommended to prevent a recurrence and/or to increase a relapse-free period in patients with  early stages of RCC. While using this vaccine, one should follow the Fuhrman histological gradation system and use a coordinated multi-  disciplinary approach to treating this group of patients. This paper describes the Fuhrman histological gradation system, indications for the  use of Oncophage in patients with the early stages of ECC and a moderate risk of a recurrence. The role of urological surgeons, oncologists,  and pathomorphologists in the treatment of patients with early stages of ECC is also considered.    

Прогностическая ценность системы гистологической градации почечно-клеточного рака (ПКР) по Fuhrman была подтверждена многочисленными исследованиями. Высокая степень градации по Fuhrman при ПКР является признаком высокого риска развития рецидива даже у больных с ранними стадиями заболевания, особенно при светлоклеточной опухоли. Для предотвращения рецидива заболевания и/или увеличения безрецидивного периода пациентам с на- чальными стадиями ПКР рекомендована противораковая вакцина Онкофаг. При назначении этой вакцины необходимо руководствоваться системой гис- тологической градации по Fuhrman и использовать скоординированый многопрофильный подход к лечению данной группы больных. В статье представлено описание системы гистологической градации по Fuhrman, даны показания для применения Онкофага у больных с ранними стадиями ПКР и умеренным ри ском развития рецидива, а также рассмотрена роль хирургов-урологов, онкологов и патоморфологов в лечении пациентов с начальными стадиями ПКР 

renal cell cancerFuhrman's nuclear gradeoncophage vaccineпочечно-клеточный ракстепень злокачественности по Fuhrmanвакцина Онкофаг1. Wood C., Srivastava P., Bukowski R. et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008;372(9633):145—54.Wood C., Srivastava P., Bukowski R. et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008;372(9633):145—54.2. Fuhrman S.A., Lasky L.C., Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6(7):655—63.Fuhrman S.A., Lasky L.C., Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6(7):655—63.3. Zisman A., Pantuck A.J., Dorey F. et al. Mathematical model to predict individual survival for patients with renal cell carcino- ma. J Clin Oncol 2002;20(5):1368—74.Zisman A., Pantuck A.J., Dorey F. et al. Mathematical model to predict individual survival for patients with renal cell carcino- ma. J Clin Oncol 2002;20(5):1368—74.4. Sika-Paotonu D., Bethwaite P.B., McCredie M.R. et al. Nucleolar grade but not Fuhrman grade is applicable to papil- lary renal cell carcinoma. Am J Surg Pathol 2006;30(9):1091—6.Sika-Paotonu D., Bethwaite P.B., McCredie M.R. et al. Nucleolar grade but not Fuhrman grade is applicable to papil- lary renal cell carcinoma. Am J Surg Pathol 2006;30(9):1091—6.5. Lohse C.M., Blute M.L., Zincke H. et al. Comparison of standardized and nonstan- dardized nuclear grade of renal cell carci- noma to predict outcome among 2,042 patients. Am J Clin Pathol 2002;118(6):877—86.Lohse C.M., Blute M.L., Zincke H. et al. Comparison of standardized and nonstan- dardized nuclear grade of renal cell carci- noma to predict outcome among 2,042 patients. Am J Clin Pathol 2002;118(6):877—86.6. Medeiros L.J., Jones E.C., Aizawa S. et al. Grading of renal cell carcinoma: Workgroup №2. Union Internationale Contre le Cancer and the American Joint Committee on Cancer (AJCC). Cancer 1997;80(5):990—1.Medeiros L.J., Jones E.C., Aizawa S. et al. Grading of renal cell carcinoma: Workgroup №2. Union Internationale Contre le Cancer and the American Joint Committee on Cancer (AJCC). Cancer 1997;80(5):990—1.7. Grignon D.J., Ayala A.G., El-Naggar A. et al. Renal cell carcinoma. A clinicopatho- logic and DNA flow cytometric analysis of 103 cases. Cancer 1989;64(10):2133—40.Grignon D.J., Ayala A.G., El-Naggar A. et al. Renal cell carcinoma. A clinicopatho- logic and DNA flow cytometric analysis of 103 cases. Cancer 1989;64(10):2133—40.8. Munichor M., Lichtig C., Tzin G., Weiss A. Prognostic significance of granular cell content in renal cell carcinoma. Eur Urol 1992;22(3):204—8.Munichor M., Lichtig C., Tzin G., Weiss A. Prognostic significance of granular cell content in renal cell carcinoma. Eur Urol 1992;22(3):204—8.9. Bretheau D., Lechevallier E., de Fromont M. et al. Prognostic value of nuclear grade of renal cell carcinoma. Cancer 1995;76(12):2543—9.Bretheau D., Lechevallier E., de Fromont M. et al. Prognostic value of nuclear grade of renal cell carcinoma. Cancer 1995;76(12):2543—9.10. Usubutun A., Uygur M.C., Ayhan A. et al. Comparison of grading systems for estimating the prognosis of renal cell carci- noma. Int Urol Nephrol 1998;30(4):391—7.Usubutun A., Uygur M.C., Ayhan A. et al. Comparison of grading systems for estimating the prognosis of renal cell carci- noma. Int Urol Nephrol 1998;30(4):391—7.11. Tsui K.H., Shvarts O., Smith R.B. et al. Prognostic indicators for renal cell carcino- ma: a multivariate analysis of 643 patients using the revised 1997 TNM staging crite- ria. J Urol 2000;163(4):1090-5; quiz 1295.Tsui K.H., Shvarts O., Smith R.B. et al. Prognostic indicators for renal cell carcino- ma: a multivariate analysis of 643 patients using the revised 1997 TNM staging crite- ria. J Urol 2000;163(4):1090-5; quiz 1295.12. Ficarra V., Righetti R., Martignoni G. et al. Prognostic value of renal cell carcino- ma nuclear grading: multivariate analysis of 333 cases. Urol Int 2001;67(2):130—4.Ficarra V., Righetti R., Martignoni G. et al. Prognostic value of renal cell carcino- ma nuclear grading: multivariate analysis of 333 cases. Urol Int 2001;67(2):130—4.13. Minervini A., Lilas L., Minervini R., Selli C. Prognostic value of nuclear grading in patients with intracapsular (pT1-pT2) renal cell carcinoma. Long-term analysis in 213 patients. Cancer 2002;94(10):2590—5.Minervini A., Lilas L., Minervini R., Selli C. Prognostic value of nuclear grading in patients with intracapsular (pT1-pT2) renal cell carcinoma. Long-term analysis in 213 patients. Cancer 2002;94(10):2590—5.14. Amin M.B., Tamboli P., Javidan J. et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 2002;26(3):281—91.Amin M.B., Tamboli P., Javidan J. et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 2002;26(3):281—91.15. Ficarra V., Prayer-Galetti T., Novella G. et al. Incidental detection beyond patho- logical factors as prognostic predictor of renal cell carcinoma. Eur Urol 2003;43(6):663—9.Ficarra V., Prayer-Galetti T., Novella G. et al. Incidental detection beyond patho- logical factors as prognostic predictor of renal cell carcinoma. Eur Urol 2003;43(6):663—9.16. Erdogan F., Demirel A., Polat O. Prognostic significance of morphologic parameters in renal cell carcinoma. Int J Clin Pract 2004;58(4):333—6.Erdogan F., Demirel A., Polat O. Prognostic significance of morphologic parameters in renal cell carcinoma. Int J Clin Pract 2004;58(4):333—6.17. Ficarra V., Martignoni G., Maffei N. et al. Original and reviewed nuclear grading according to the Fuhrman system: a multi- variate analysis of 388 patients with con- ventional renal cell carcinoma. Cancer 2005;103(1):68—75.Ficarra V., Martignoni G., Maffei N. et al. Original and reviewed nuclear grading according to the Fuhrman system: a multi- variate analysis of 388 patients with con- ventional renal cell carcinoma. Cancer 2005;103(1):68—75.18. Patard J.J., Leray E., Rioux-Leclercq N. et al. Prognostic value of histologic sub- types in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005;23(12):2763—71.Patard J.J., Leray E., Rioux-Leclercq N. et al. Prognostic value of histologic sub- types in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005;23(12):2763—71.19. Novara G., Martignoni G., Artibani W., Ficarra V. Grading systems in renal cell carcinoma. J Urol 2007;177(2):430—6.Novara G., Martignoni G., Artibani W., Ficarra V. Grading systems in renal cell carcinoma. J Urol 2007;177(2):430—6.20. Goldstein N.S. The current state of renal cell carcinoma grading. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80(5):977—80.Goldstein N.S. The current state of renal cell carcinoma grading. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80(5):977—80.21. Zisman A., Pantuck A.J., Wieder J. et al. Risk group assessment and clinical out- come algorithm to predict the natural his- tory of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002;20(23):4559—66.Zisman A., Pantuck A.J., Wieder J. et al. Risk group assessment and clinical out- come algorithm to predict the natural his- tory of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002;20(23):4559—66.22. Al-Aynati M., Chen V., Salama S. et al. Interobserver and intraobserver variability using the Fuhrman grading system for renal cell carcinoma. Arch Pathol Lab Med 2003;127(5):593—6.Al-Aynati M., Chen V., Salama S. et al. Interobserver and intraobserver variability using the Fuhrman grading system for renal cell carcinoma. Arch Pathol Lab Med 2003;127(5):593—6.23. Engers R. Reproducibility and reliabil- ity of tumor grading in urological neo- plasms. World J Urol 2007;25(6):595—605.Engers R. Reproducibility and reliabil- ity of tumor grading in urological neo- plasms. World J Urol 2007;25(6):595—605.24.Goldstein N.S. Grading of renal cell carcinoma. Urol Clin North Am 1999;26(3):637—42.Goldstein N.S. Grading of renal cell carcinoma. Urol Clin North Am 1999;26(3):637—42.25. Lang H., Lindner V., de Fromont M. et al. Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma: Assessment of 241 patients with > 15-year follow-up. Cancer 2005;103(3):625—9.Lang H., Lindner V., de Fromont M. et al. Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma: Assessment of 241 patients with > 15-year follow-up. Cancer 2005;103(3):625—9.26. Lanigan D., Conroy R., Barry-Walsh C. et al. A comparative analysis of grading sys- tems in renal adenocarcinoma. Histopathology 1994;24(5):473—6.Lanigan D., Conroy R., Barry-Walsh C. et al. A comparative analysis of grading sys- tems in renal adenocarcinoma. Histopathology 1994;24(5):473—6.27. Frank I., Blute M.L., Cheville J.C. et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002;168(6):2395—400.Frank I., Blute M.L., Cheville J.C. et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002;168(6):2395—400.28. Kunkle D.A., Haas N.B., Uzzo R.G. Adjuvant therapy for high-risk renal cell carcinoma patients. Curr Urol Rep 2007;8(1):19—30.Kunkle D.A., Haas N.B., Uzzo R.G. Adjuvant therapy for high-risk renal cell carcinoma patients. Curr Urol Rep 2007;8(1):19—30.29. Lam J.S., Shvarts O., Leppert J.T. et al. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 2005;174:466—72.Lam J.S., Shvarts O., Leppert J.T. et al. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 2005;174:466—72.30. Francois C., Decaestecker C., De Lathouwer O. et al. Improving the prognostic value of histopathological grad- ing and clinical staging in renal cell carci- nomas by means of computer-assisted microscopy. J Pathol 1999;187(3):313—20.Francois C., Decaestecker C., De Lathouwer O. et al. Improving the prognostic value of histopathological grad- ing and clinical staging in renal cell carci- nomas by means of computer-assisted microscopy. J Pathol 1999;187(3):313—20.31. Patard J.J., Kim H.L., Lam J.S. et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an interna- tional multicenter study. J Clin Oncol 2004;22(16):3316—22.Patard J.J., Kim H.L., Lam J.S. et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an interna- tional multicenter study. J Clin Oncol 2004;22(16):3316—22.32. Rosen L.S., Bilchik A.J., Beart R.W. Jr. et al. New approaches to assessing and treating early-stage colon and rectal cancer: summary statement from 2007 Santa Monica Conference. Clin Cancer Res 2007;13(22 Pt 2):6853—6.Rosen L.S., Bilchik A.J., Beart R.W. Jr. et al. New approaches to assessing and treating early-stage colon and rectal cancer: summary statement from 2007 Santa Monica Conference. Clin Cancer Res 2007;13(22 Pt 2):6853—6.33. Taal B.G., Van Tinteren H., Zoetmulder F.A. Adjuvant 5FU plus lev- amisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 2001;85(10):1437—43.Taal B.G., Van Tinteren H., Zoetmulder F.A. Adjuvant 5FU plus lev- amisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 2001;85(10):1437—43.34. Effects of chemotherapy and hormonal therapy for early breast cancer on recur- rence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687—717.Effects of chemotherapy and hormonal therapy for early breast cancer on recur- rence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687—717.35. Rakkhit R., Broglio K., Peintinger F., Cardoso F. Significant increase recurrence rates among breast cancer patients with Her-2-positive, T1a,bN0M0 tumors [abstract 701]. Paper presented at: San Antonio Breast Cancer Conference 2008; December 13, 2008. San Antonnio, Texas.Rakkhit R., Broglio K., Peintinger F., Cardoso F. Significant increase recurrence rates among breast cancer patients with Her-2-positive, T1a,bN0M0 tumors [abstract 701]. Paper presented at: San Antonio Breast Cancer Conference 2008; December 13, 2008. San Antonnio, Texas.36. Chau I., Cunningham D. Adjuvant therapy in colon cancer-what, when and how? Ann Oncol 2006;17(9):1347—59.Chau I., Cunningham D. Adjuvant therapy in colon cancer-what, when and how? Ann Oncol 2006;17(9):1347—59.37. Moertel C.G., Fleming T.R., Macdonald J.S. et al. Levamisole and fluo- rouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322(6):352—8.Moertel C.G., Fleming T.R., Macdonald J.S. et al. Levamisole and fluo- rouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322(6):352—8.38. Andre T., Boni C., Mounedji-Boudiaf L. et al. Oxaliplatin, fluorouracil, and leucov- orin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343—51.Andre T., Boni C., Mounedji-Boudiaf L. et al. Oxaliplatin, fluorouracil, and leucov- orin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343—51.39. Vermorken J.B., Claessen A.M., van Tinteren H. et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999;353(9150):345—50.Vermorken J.B., Claessen A.M., van Tinteren H. et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999;353(9150):345—50.